CD3 Antibody CDR Engineering for Lower Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing a CD3 targeting antibody that achieves a good immune response and serum titer is challenging, leading to a small number of positive clones, and existing antibodies like OKT3 have significant side effects and limited cross-reactivity with non-human primate CD3, complicating preclinical safety evaluations.
Innovation Solution
A new anti-CD3 antibody with specific CDR sequences that bind to human and cynomolgus CD3, providing low side effects and facilitating preclinical studies by enabling the use of cynomolgus models, and activating the NFAT downstream signaling pathway in human T cell lines.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CD3 antibodies like OKT3 are used, then T cell function can be modulated, but significant side effects including flu-like syndrome and cytokine storm occur
Solution Approach 1:
The patent applies parameter changes by developing a new antibody with modified CDR sequences (specifically heavy chain CDR1: NYYMH, CDR2: WTYPGNNNIKYNEKFKG, CDR3: DGYGYYFFDY) that alters the binding characteristics to CD3. This sequence modification changes the interaction parameters with T cells, achieving similar immunomodulatory effects while reducing harmful side effects through optimized binding affinity and specificity.
Solution Approach 2:
The invention applies local quality by specifically modifying the CDR regions (complementarity determining regions) of the antibody while maintaining the overall IgG1 structure. The localized changes in the CDR sequences enhance binding to human CD3 and reduce cross-reactivity with cynomolgus CD3, thereby improving safety profile while preserving therapeutic function.
2Reliability
If existing CD3 antibodies are used, then treatment effect is achieved, but cross-reactivity with cynomolgus CD3 is limited, complicating preclinical safety evaluations
Solution Approach 1:
The patent uses parameter changes by designing CDR sequences with specific amino acid compositions that create species-specific binding preferences. The heavy chain CDR sequences (NYYMH, WTYPGNNNIKYNEKFKG, DGYGYYFFDY) are engineered to have higher affinity for human CD3 epitopes while showing reduced cross-reactivity with cynomolgus monkey CD3, enabling better preclinical modeling in humanized or transgenic systems.
Solution Approach 2:
The antibody design achieves a form of controlled universality by maintaining broad binding capability across human CD3 variants (CD3ε, γ, δ, ζ chains) while introducing selective discrimination against cynomolgus CD3. This selective universality allows the antibody to function effectively in human therapeutic contexts while enabling appropriate preclinical safety assessment in non-primate models.
3Reliability
If CD3 targeting antibody development is pursued, then therapeutic potential is achieved, but it is difficult to obtain good immune response and serum titer, resulting in small number of positive clones
Solution Approach 1:
The patent applies preliminary action by pre-defining the optimal CDR sequences based on known CD3 epitope structures and antibody-antigen interaction principles. Rather than relying on random immunization and screening, the invention uses rational design to establish the heavy chain CDR sequences (NYYMH, WTYPGNNNIKYNEKFKG, DGYGYYFFDY) before production, significantly increasing the likelihood of obtaining functional antibodies with desired properties.
Solution Approach 2:
The invention employs copying by utilizing the successful binding paradigm from established CD3 antibodies like OKT3 as a template, then making targeted sequence modifications to the CDR regions. This approach copies the proven structural framework and binding mode while introducing specific sequence changes to improve therapeutic index and reduce side effects, thereby increasing productivity of viable candidates.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody achieves high affinity binding to human and cynomolgus CD3, reducing side effects and enhancing the suitability of cynomolgus models for pharmacological and toxicological studies, while effectively activating relevant signaling pathways.
Implementation Method 1
The TCR/CD3 complex is the main regulator of T cell function and specificity in humans and other mammals, and plays a very important role in antigen recognition and intracellular signal transduction pathways
Implementation Method 2
its intracellular region is very short and needs to form a TCR/CD3 complex with CD3 to transduce stimulation signals into a cell
Data Source
AI summary
The present disclosure relates to a CD3-targeting antibody and use thereof. Specifically, the present disclosure provides an antibody or antigen-binding fragment thereof that specifically binds to CD3, a nucleic acid encoding the antibody or antigen-binding fragment thereof, a nucleic acid vector comprising the nucleic acid, a host cell comprising the nucleic acid or nucleic acid vector, a pharmaceutical composition comprising the aforementioned substances, and a preparation method therefor and use thereof.